CRISPR Therapeutics
CRSP
417 hedge funds and large institutions have $3.07B invested in CRISPR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 94 increasing their positions, 137 reducing their positions, and 27 closing their positions.
141% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 27
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
27% more call options, than puts
Call options by funds: $142M | Put options by funds: $112M
9% more funds holding
Funds holding: 382 → 417 (+35)
2.09% less ownership
Funds ownership: 71.49% → 69.41% (-2.1%)
31% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 137
32% less capital inflows, than outflows
Capital inflows: $171M | Capital outflows: $250M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$25.9M |
| 2 |
Frontier Capital Management
Boston,
Massachusetts
|
+$18.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$13.4M |
| 4 |
Contrarius Investment Management
St. Helier,
Jersey
|
+$13M |
| 5 |
Two Sigma Investments
New York
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
-$37M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$25M |
| 3 |
Nikko Asset Management Americas
New York
|
-$24.9M |
| 4 |
State Street
Boston,
Massachusetts
|
-$20.1M |
| 5 |
Armistice Capital
New York
|
-$18.4M |
CRSP Hedge Fund Activity: Q2 2023 in Review
417 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2023, worth a combined $3.07B — up 21% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new CRSP positions and 27 closed out — a net gain of 38 holders — while 94 added to existing stakes and 137 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $25.9M. The largest seller was ARK Investment Management, cutting an estimated $37M.
- 417 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2023, up from 382 in Q1 2023.
- Funds reported $3.07B of CRISPR Therapeutics stock for Q2 2023, up 21% quarter-over-quarter.
- 65 funds opened new CRISPR Therapeutics positions in Q2 2023 and 27 closed out, a net change of +38 holders.
- The largest CRISPR Therapeutics buyer in Q2 2023 was Marshall Wace, an estimated $25.9M added.
- The largest CRISPR Therapeutics seller in Q2 2023 was ARK Investment Management, an estimated $37M sold.
Based on aggregated 13F filings for Q2 2023.